Myeloma immunoglobulin idiotype (Id)

The myeloma immunoglobulin idiotype is the unique antigenic signature found in the variable regions (VH and VL) of the monoclonal immunoglobulin (M-protein) secreted by malignant plasma cells (Yi et al., 2003). These idiotypic determinants arise from the unique V(D)J recombination and somatic hypermutation events that occurred in the B-cell progenitor of the myeloma clone, making them true tumor-specific neoantigens (Massaia et al., 1999). Because this sequence is absent from normal tissues and healthy B cells, it serves as an ideal target for precision immunotherapy designed to spare non-malignant cells. Therapeutic strategies typically involve the administration of personalized idiotype vaccines, where the patient's specific M-protein is purified or recombinantly expressed and often conjugated to an immunogenic carrier like Keyhole Limpet Hemocyanin (KLH) (Bahlis et al., 2002). These vaccines are frequently co-administered with adjuvants such as Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) to enhance the recruitment and activation of antigen-presenting cells. The primary mechanism of action is the induction of idiotype-specific cytotoxic T lymphocytes (CTLs) and helper T-cells that recognize and eliminate the malignant plasma cell population (Hansson et al., 2007). Despite the high specificity of this approach, clinical success has been hindered by the inherent low immunogenicity of these self-derived proteins and the significant logistical challenges associated with manufacturing individualized treatments for every patient (Bendandi, 2009).

Other names

M-protein idiotypeTumor-specific idiotypeMyeloma neoantigenImmunoglobulin variable region idiotypeV-region neoantigen

Active immunization to induce host T-cell and B-cell mediated immune responses against the unique variable regions of the monoclonal immunoglobulin produced by malignant plasma cells.